Premium
Valproic Acid Enhances iPSC Induction From Human Bone Marrow‐Derived Cells Through the Suppression of Reprogramming‐Induced Senescence
Author(s) -
Chen Xi,
Zhai Yingying,
Yu Dehai,
Cui Jiuwei,
Hu JiFan,
Li Wei
Publication year - 2016
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.25270
Subject(s) - klf4 , reprogramming , induced pluripotent stem cell , microbiology and biotechnology , sox2 , biology , histone deacetylase inhibitor , transfection , histone deacetylase , trichostatin a , cancer research , cell , cell culture , histone , transcription factor , embryonic stem cell , biochemistry , genetics , gene
Reprogramming of human somatic cells into pluripotent cells (iPSCs) by defined transcription factors is an extremely inefficient process. Treatment with the histone deacetylase inhibitor valproic acid (VPA) during reprogramming can improve the induction of iPSCs. To examine the specific mechanism underlying the role of VPA in reprogramming, we transfected human bone marrow‐derived cells (HSC‐J2 and HSC‐L1) with lentiviruses carrying defined factors (OCT4, SOX2, KLF4, and c‐MYC, OSKM) in the presence of VPA. We found that, OSKM lentiviruses caused significant senescence in transfected cells. Administration of VPA, however, significantly suppressed this reprogramming‐induced stress. Notably, VPA treatment improved cell proliferation in the early stages of reprogramming, and this was related to the down‐regulation of the activated p16/p21 pathway. In addition, VPA also released the G2/M phase blockade in lentivirus‐transfected cells. This study demonstrates a new mechanistic role of the histone deacetylase inhibitor in enhancing the induction of pluripotency. J. Cell. Physiol. 231: 1719–1727, 2016. © 2015 Wiley Periodicals, Inc.